Inhibitor Therapeutics Total Assets

Inhibitor Therapeutics posts a total assets of $640K as of June 2026. That compares with $3.9M in the prior-year period — down 83.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Inhibitor Therapeutics's total assets was $3.9M. The latest reading is $640K — a 83.7% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Assets is one piece of Inhibitor Therapeutics's financial statement story. At $640K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for INTI's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Inhibitor Therapeutics's other metric pages and overview cover the third.

Judging Inhibitor Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $640K here, then scan peer and history charts to see if the gap is persistent.